EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combining plasma neurofilament light chain and frontotemporal atrophy improves differentiation of bvFTD from primary psychiatric disorders

Sean Coulborn iD, Ashlin R K Roy, Andrzej Sokolowski, Noah G Cryns, Argentina Lario Lago, Yann Cobigo, Julio C Rojas, Salvatore Spina, Lea T Grinberg, Katherine P Rankin, Adam L Boxer, Andrew D Krystal und 7 weitere

Alzheimer's & Dementia · 2025-10 · 21 (10)

DOI: 10.1002/alz.70771 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 08.10.2025. Verfasst von Sean Coulborn und 18 weiteren Autor:innen. Beteiligte Einrichtung: Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, Cali…. Hauptthemen laut MEDLINE: Neurofilament Proteins, Frontotemporal Dementia, Mental Disorders, Mood Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rainwater Charitable Foundation and the Bluefield Project to Cure FTD, NIA NIH HHS, ALLFTD Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Distinguishing behavioral variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PPDs) remains challenging due to overlapping clinical presentation. Neurofilament light chain (NfL) is a biomarker of neuronal damage that is elevated in neurodegenerative diseases. This study assessed the effectiveness of NfL and atrophy in differentiating bvFTD from PPDs. METHODS Atrophy maps from frontotemporal regions were generated for 55 patients with autopsy‐confirmed frontotemporal lobar degeneration (bvFTD‐FTLD), 24 mood disorder patients, and eight bvFTD patients later determined to be non‐neurodegenerative (bvFTD‐nonND). Logistic regression was employed to assess the discriminatory abilities of atrophy and NfL levels between bvFTD‐FTLD and PPD (Mood Disorders + bvFTD‐nonND). RESULTS Both atrophy (AUC = 0.87, 95% confidence interval [95% CI: 0.79 to 0.94]) and NfL (AUC = 0.89, 95% CI: 0.81 to 0.96) showed significant predictive ability, which improved when combined (AUC = 0.93, 95% CI: 0.87 to 0.99). Misclassification occurred mostly in low atrophy pathological subtypes and PPD with borderline NfL and frontotemporal volume. CONCLUSION Combining NfL with atrophy enhances differentiation, but additional markers are needed. Highlights Atrophy and NfL had comparable effectiveness in differentiating bvFTD from PPD. Combining NfL and frontotemporal atrophy significantly improved predictive accuracy. NfL, in addition to atrophy, may be beneficial in screening for neurodegeneration in ambiguous cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsFrontotemporal DementiaMental DisordersMood DisordersHumansMaleFemaleAtrophyAgedMiddle AgedBiomarkersDiagnosis, DifferentialMagnetic Resonance ImagingBrain

Stichwörter der Autor:innen

behavioral variant frontotemporal dementiabiological markersfrontotemporal dementiafrontotemporal lobar degenerationneurofilament light chainneuroimagingprimary psychiatric disorders

Substanzen

Neurofilament Proteinsneurofilament protein LBiomarkers

Autor:innen und Institutionen

  • Memory and Aging Center, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
  • Department of Pathology, University of California, San Francisco, California, USA.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
  • Veterans Affairs Medical Center, San Francisco, California, USA.

ORCID-Profile: Sean Coulborn

Förderung

  • Rainwater Charitable Foundation and the Bluefield Project to Cure FTD
  • NIA NIH HHS
  • ALLFTD Consortium
  • NIH HHS
  • National Centralized Repository for Alzheimer's Disease and Related Dementias
  • National Institute of Neurological Diseases and Stroke
  • NCATS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Coulborn, S., Roy, A. R. K., Sokolowski, A., Cryns, N. G., Lago, A. L., Cobigo, Y., Rojas, J. C., Spina, S., Grinberg, L. T., Rankin, K. P., Boxer, A. L., Krystal, A. D., Mackin, R. S., Kramer, J. H., Miller, B. L., Seeley, W. W., Rosen, H. J., VandeVrede, L., & Perry, D. C. (2025). Combining plasma neurofilament light chain and frontotemporal atrophy improves differentiation of bvFTD from primary psychiatric disorders. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70771

Vancouver

Coulborn S, Roy ARK, Sokolowski A, Cryns NG, Lago AL, Cobigo Y, et al. Combining plasma neurofilament light chain and frontotemporal atrophy improves differentiation of bvFTD from primary psychiatric disorders. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70771

BibTeX
@article{Coulborn2025,
  author = {Coulborn, Sean and Roy, Ashlin R K and Sokolowski, Andrzej and Cryns, Noah G and Lago, Argentina Lario and Cobigo, Yann and Rojas, Julio C and Spina, Salvatore and Grinberg, Lea T and Rankin, Katherine P and Boxer, Adam L and Krystal, Andrew D and Mackin, R Scott and Kramer, Joel H and Miller, Bruce L and Seeley, William W and Rosen, Howard J and VandeVrede, Lawren and Perry, David C},
  title = {Combining plasma neurofilament light chain and frontotemporal atrophy improves differentiation of bvFTD from primary psychiatric disorders},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {10},
  doi = {10.1002/alz.70771}
}
Kostenlos starten →